$HURA News

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

HURA: Refining TBS-2025 Development Plan

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Citizens Initiates Coverage On TuHURA Biosciences with Market Outperform Rating, Announces Price Target of $9

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses

Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

HURA: 2025 Financial Results

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent